The Providence Valve Center was founded in 2011 when the team at Providence St. Vincent was selected, based on a long history of excellence in surgical management of heart valve disease, to participate in the pivotal PARTNER II, randomized clinical trial establishing the safety of Transcatheter Aortic Valve Replacement (TAVR) in patients that were at least intermediate risk for traditional Surgical Aortic Valve Replacement (SAVR).
Over the subsequent years, the Providence Valve Center has endeavored to continue this tradition by bringing the most cutting edge technologies to patients in the Pacific Northwest through active participation in clinical research. Other landmark studies have included the recently published COAPT trial of the MitraClip device to treat patients with heart failure and mitral regurgitation, the PARTNER 3 trial of TAVR in patients who are low risk for surgery, and many others.
Our team is also a national leader in developing safe ways to perform transcatheter aortic valve replacement in patients that have inadequate femoral arteries for the most common approach, and have performed more TAVR procedures through the Carotid artery than any program in the United States. We were also the first program in the state of Oregon to utilize the Sentinel Cerebral Embolic Protection filter system to minimize the risk of stroke events during TAVR.
Our team has now performed more than 1,400 transcatheter valve procedures including TAVR, MitraClip, and valve-in-valve procedures for patients with failing aortic, mitral, or tricuspid valves.
The goal of our dedicated team of Interventional Cardiologists, Cardiac Surgeons, Advanced Practice Providers, Palliative Care Specialists, and Nurse Coordinators is to understand each patient’s condition, goals, and priorities for their care, and match that to the best possible treatment for each individual. Continue reading below for a comprehensive list of the conditions we treat and active research protocols that are available to our patients.